|Day's Range||39.00 - 39.00|
Peter Diamandis, Celularity co-founder and vice chairman, and Bob Hariri, Celularity co-founder, chairman and CEO, talk about the future of cellular medicine as scientist develop ways to reengineer living cells.
Celgene Corporation today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology Annual Meeting.
Celgene Corporation (NASDAQ:CELG) delivered an ROE of 42.48% over the past 12 months, which is an impressive feat relative to its industry average of 16.36% during the same period. WhileRead More...
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
Bridgewater Associates, the firm of hedge fund billionaire Ray Dalio, took large positions in ETFs, 13F filings show.
College Retirement Equities Fund, known as TIAA, has reached its 100th year since being founded by Andrew Carnegie. Teachers Advisors, an investment advisor unit of TIAA, turns a mere 25 this year. It manages $78 billion in U.S.-traded securities, and in the fourth quarter it made some bold stock trades that showed it has nerves of steel.
WARREN, N.J. , Feb. 15, 2018 /PRNewswire/ -- Celularity has been created through the contribution and acquisition of extensive intellectual property, clinical-stage assets, basic and clinical research, ...
Celgene Corporation announced that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had failed at least one conventional therapy but were naïve to biologic therapy were presented in an oral session today at the 13th Congress of ECCO in Vienna (Abstract OP006, 3:30 p.m.
Celularity, a company spun out of biotech giant Celgene, announced this morning it has raised $250 million with the aim of developing cells from placentas to attack tumors and to treat Crohn’s disease. In addition to being awash in cash, the company is flooded with big dreams.
Celgene Corp. and other corporate and financial investors are funneling more than $250 million into a startup formed to develop treatments for cancer, inflammation and other diseases.
Celgene Corporation today announced the election of John Weiland to its Board of Directors. Mr. Weiland has over 30 years in the healthcare industry and was most recently the President and Chief Operating Officer of C.
Former Celgene Chairman and CEO Bob Hugin says the U.S. is failing to adequately address the increasing inequality of health care.
Celgene Corp. said Wednesday its board has approved an additional $5 billion share buyback. Shares rose 1.1% premarket, but are down 21% in the last 12 months, while the S&P 500 has gained 14%.
Celgene Corporation today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock. This open-ended program is effective immediately.
Bob Hugin, the former chief executive and chairman of drug giant Celgene Corp., plans to announce his run for Senate Tuesday in the company’s home state of New Jersey.
After 4Q17, Amgen (AMGN) anticipates its net revenues for 2018 to be $21.8 billion–$22.8 billion. It expects non-GAAP (generally accepted accounting principles) to be $12.60–$13.70 and its tax rate to be 14%–15%. Amgen estimated capital expenditure for 2018 of $750 million.